Author

Caroline Capdevielle

Hôpital Maisonneuve-RosemontORCID 0009-0002-4995-852XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:metagenomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alejandro Schcolnik‐CabreraiD· 1 shared Anavasadat Sadr Hashemi NejadiD· 1 shared April A. N. RoseiD· 1 shared Donia Issa· 1 shared Frédérick A. MalletteiD· 1 shared Ivan TopisirovićiD· 1 shared Laura HuleaiD· 1 shared Martín RofféiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alejandro Schcolnik‐CabreraORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintSep 8, 2026

eIF4A inhibition disrupts resistance-associated translational and metabolic programs in BRAF-mutant melanoma

Alejandro Schcolnik‐Cabrera, Meriem Takdenti, Anavasadat Sadr Hashemi Nejad…·Laura Hulea

This study shows eIF4A inhibition disrupts resistance mechanisms in BRAF-mutant melanoma by targeting translational and metabolic programs, improving tumor control when combined with BRAF inhibitors.

DOI 10.64898/2026.09.03.749206

humanbulk RNA-seq

𝕏 PostBluesky